Loading company
INVO Fertility, Inc.
IVF · Nasdaq · ·
$0.93-1.5%Sep 28 close
- 1M
- -7.0%
- 6M
- -59.0%
- 1Y
- -96.9%
IVF · Nasdaq · ·
$0.93-1.5%Sep 28 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2.2M | $1.9M | +16.73% |
| Profit | $888.7K | -$3.6M | +124.56% |
| Profit per share | $0.35 | -$0.01 | +2,992.56% |
| Free Cash Flow | $13.4K | -$696.3K | +101.92% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
INVO Fertility, Inc. has no earnings call transcript available.
“The second quarter continued the progress we demonstrated in the first quarter and provided further validation of our strategy,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Fertility We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on US-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from INVO Fertility, Inc.’s Item 2.02 8-K filed August 17, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.